B
Brandon Luber
Researcher at Johns Hopkins University
Publications - 49
Citations - 24678
Brandon Luber is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Prostate cancer & Enzalutamide. The author has an hindex of 26, co-authored 49 publications receiving 19451 citations. Previous affiliations of Brandon Luber include Johns Hopkins University School of Medicine & Howard Hughes Medical Institute.
Papers
More filters
Journal ArticleDOI
PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival
Evan J. Lipson,Jeremy G. Vincent,Myriam Loyo,Luciane T. Kagohara,Brandon Luber,Hao Wang,Haiying Xu,Suresh K. Nayar,Timothy S. Wang,David Sidransky,Robert A. Anders,Suzanne L. Topalian,Janis M. Taube +12 more
TL;DR: It is suggested that a local tumor-specific and potentially MCPyV-specific immune response drives tumor PD-L1 expression, similar to previous observations in melanoma and head and neck squamous cell carcinomas.
Journal ArticleDOI
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
Benjamin A. Teply,Benjamin A. Teply,Hao Wang,Brandon Luber,Rana Sullivan,Irina Rifkind,Ashley Bruns,Avery Spitz,Morgan Decarli,Victoria J. Sinibaldi,Caroline F. Pratz,Changxue Lu,John L. Silberstein,Jun Luo,Michael T. Schweizer,Michael T. Schweizer,Charles G. Drake,Charles G. Drake,Michael A. Carducci,Channing J. Paller,Emmanuel S. Antonarakis,Mario A. Eisenberger,Samuel R. Denmeade +22 more
TL;DR: Bipolar androgen therapy is a safe therapy that resulted in responses in asymptomatic men with metastatic castration-resistant prostate cancer and also resensitisation to enzalutamide in most patients undergoing rechallenge.
Journal ArticleDOI
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Emmanuel S. Antonarakis,Changxue Lu,Brandon Luber,Chao Liang,Hao Wang,Yan Chen,John L. Silberstein,Danilo Piana,Zhao Lai,Yi Chen,William B. Isaacs,Jun Luo +11 more
TL;DR: Outcomes to first-line NHT appear better in mCRPC patients harboring germline BRCA/ATM mutations (vs no mutations), but not for patients with other non-BRCA /ATM germline mutations, and these results require prospective validation.
Journal ArticleDOI
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.
Karim Boudadi,Daniel L. Suzman,Valsamo Anagnostou,Wei Fu,Brandon Luber,Hao Wang,Noushin Niknafs,James R. White,John L. Silberstein,Rana Sullivan,Donna Dowling,Rana Harb,Thomas R. Nirschl,Brendan A. Veeneman,Brendan A. Veeneman,Scott A. Tomlins,Yipeng Wang,Adam Jendrisak,Ryon P. Graf,Ryan Dittamore,Michael A. Carducci,Mario A. Eisenberger,Michael C. Haffner,Alan K. Meeker,James R. Eshleman,Jun Luo,Victor E. Velculescu,Charles G. Drake,Emmanuel S. Antonarakis +28 more
TL;DR: Ipilimumab plus nivolumab demonstrated encouraging efficacy in AR-V7-positive prostate cancers with DRD mutations, but not in the overall study population.
Journal ArticleDOI
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
TL;DR: Evaluated the clinical activity of enzalutamide versus docetaxel in men with mCRPC who progressed on abiraterone to determine whether subsequent taxane‐based chemotherapy may be more effective than sequential AR‐targeting treatment.